Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Galirayo who wrote (1047)	6/15/2005 11:18:31 PM
From: John Metcalf	Read Replies (3) \| Respond to of 3722

Thanks, Ray. It closed on the 8 EMA today. "Is it expecting News anytime soon ??" Not that I know of. In fact, there was a recent story about the crowded chase for drugs based on Vanilloid (VR1) receptors, involving many companies, most of them big pharmas. The NRGN-MRK collaboration is one of them, and notable for the generous terms. Merck put out funding and pooled their technology with NRGN. NRGN owns a piece of the outcome, regardless whether they originated the technology or Merck did. As you noted, low volume would not be consistent with expected news.